{"title":"干扰素治疗多发性硬化症的进展","authors":"O. Boyko, N. Smirnova, A. N. Boyko","doi":"10.14412/2074-2711-2023-1s-58-64","DOIUrl":null,"url":null,"abstract":"The article reviews the evolution of interferon-β (IFN-β) in the treatment of multiple sclerosis (MS) from the first high-dose interferons to the most recent pegylated forms. The results of pivotal trials are presented and discussed. The main problems of the first IFN-β were: 1) moderate efficacy in the presence of neutralizing antibodies (NAB, in 20% of treated patients), leading to a decrease in efficacy, 2) poor tolerability due to frequent injections (every other day), 3) severe local reactions and flu-like syndrome. Pegillation made it possible to extend the duration of administration to one injection every 14 days and to reduce the probability of NAB to less than 1% of all treated patients. The first drug administered subcutaneously had a pronounced flu-like syndrome; the domestic drug SamPEG-IFN-β1a administered intramuscularly was better tolerated with similar efficacy.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"42 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The evolution of interferon therapy in multiple sclerosis\",\"authors\":\"O. Boyko, N. Smirnova, A. N. Boyko\",\"doi\":\"10.14412/2074-2711-2023-1s-58-64\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The article reviews the evolution of interferon-β (IFN-β) in the treatment of multiple sclerosis (MS) from the first high-dose interferons to the most recent pegylated forms. The results of pivotal trials are presented and discussed. The main problems of the first IFN-β were: 1) moderate efficacy in the presence of neutralizing antibodies (NAB, in 20% of treated patients), leading to a decrease in efficacy, 2) poor tolerability due to frequent injections (every other day), 3) severe local reactions and flu-like syndrome. Pegillation made it possible to extend the duration of administration to one injection every 14 days and to reduce the probability of NAB to less than 1% of all treated patients. The first drug administered subcutaneously had a pronounced flu-like syndrome; the domestic drug SamPEG-IFN-β1a administered intramuscularly was better tolerated with similar efficacy.\",\"PeriodicalId\":19252,\"journal\":{\"name\":\"Neurology, neuropsychiatry, Psychosomatics\",\"volume\":\"42 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology, neuropsychiatry, Psychosomatics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14412/2074-2711-2023-1s-58-64\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology, neuropsychiatry, Psychosomatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14412/2074-2711-2023-1s-58-64","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The evolution of interferon therapy in multiple sclerosis
The article reviews the evolution of interferon-β (IFN-β) in the treatment of multiple sclerosis (MS) from the first high-dose interferons to the most recent pegylated forms. The results of pivotal trials are presented and discussed. The main problems of the first IFN-β were: 1) moderate efficacy in the presence of neutralizing antibodies (NAB, in 20% of treated patients), leading to a decrease in efficacy, 2) poor tolerability due to frequent injections (every other day), 3) severe local reactions and flu-like syndrome. Pegillation made it possible to extend the duration of administration to one injection every 14 days and to reduce the probability of NAB to less than 1% of all treated patients. The first drug administered subcutaneously had a pronounced flu-like syndrome; the domestic drug SamPEG-IFN-β1a administered intramuscularly was better tolerated with similar efficacy.